Prof Jens Hoeppner speaks to ecancer at ASCO 2024 about a phase III trial comparing preoperative chemotherapy to neoadjuvant chemoradiation in patients with adenocarcinoma of the oesophagus.

221 participants were randomised to the chemotherapy before and after surgery and 217 participants were randomised to the chemoradiotherapy before surgery arm.

Median overall survival was 66 months in the chemotherapy before and after surgery arm and 37 months in the chemoradiotherapy before surgery arm.